Blood-Based Mass Spectrometry Classifier for Prostate Cancer Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for managing prostate cancer, particularly in low-risk patients, lack reliable non-invasive tests to accurately predict disease progression, leading to challenges in selecting appropriate candidates for watchful waiting versus immediate active treatment.
Innovation Solution
A method and system utilizing mass spectrometry to analyze blood samples, processing the data with pre-processing operations and classifying them using a programmed computer with a classifier defined by master classifiers generated from filtered mini-classifiers with regularization, to predict the aggressiveness or indolence of prostate cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If mass spectrometry analysis is performed on blood-based samples, then measurement precision for predicting prostate cancer aggressiveness is improved, but device complexity increases
Solution Approach 1:
The mass spectrometry data processing is divided into multiple stages: pre-processing operations on raw spectral data, feature extraction to identify relevant mass-to-charge ratios, and classification using trained algorithms. This segmentation transforms a complex monolithic process into manageable modular components that can be implemented separately.
Solution Approach 2:
The system performs pre-processing operations on mass spectral data before classification, including normalization, background subtraction, and peak detection. These preliminary actions prepare the data in advance, improving measurement precision while organizing the complexity into distinct preparatory and analysis phases.
2Measurement precision
If invasive biopsy procedures are performed to obtain Gleason scores, then measurement precision for cancer grading is improved, but object-generated harmful factors increase
Solution Approach 1:
The patent replaces the mechanical invasive biopsy procedure with a non-invasive mass spectrometry analysis of blood-based samples. The mass spectrometer detects and quantifies proteins and other molecules in the blood that correlate with prostate cancer aggressiveness, eliminating the need for needle biopsies while providing comparable prognostic information.
Solution Approach 2:
The system uses blood-based samples as an intermediary medium to obtain cancer-related information without direct tissue sampling. The blood contains proteins and molecules that reflect the tumor characteristics, serving as a non-invasive proxy for the cancer tissue itself.
3Ease of operation
If traditional risk stratification methods are used based on PSA and TNM staging, then ease of operation is maintained, but measurement precision for predicting disease progression worsens
Solution Approach 1:
The mass spectrometry-based test serves multiple functions: it provides risk stratification similar to traditional methods while simultaneously predicting disease progression and aggressiveness. The same blood sample analysis yields information about both current disease state and future progression risk, enhancing measurement precision without adding separate procedures.
Solution Approach 2:
The system moves from measuring traditional parameters like total PSA levels to analyzing mass-to-charge ratios of specific proteins in the blood. This parameter change from bulk PSA measurement to specific protein fingerprinting improves the precision of progression prediction while maintaining the simplicity of a single blood draw procedure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach provides a non-invasive means to accurately predict prostate cancer aggressiveness or indolence, improving risk discrimination and guiding treatment decisions for patients.
Implementation Method 1
conducting mass spectrometry of the blood-based sample with a mass spectrometer and thereby obtaining mass spectral data including intensity values at a multitude of m/z features in a spectrum produced by the mass spectrometer
Data Source
AI summary
A programmed computer functioning as a classifier operates on mass spectral data obtained from a blood-based patient sample to predict indolence or aggressiveness of prostate cancer. Methods of generating the classifier and conducting a test on a blood-based sample from a prostate cancer patient using the classifier are described.